Aurinia Pharmaceuticals Stock Today
| AUPH Stock | USD 5.04 0.06 1.18% |
Performance0 of 100
| Odds Of DistressLess than 29
|
Aurinia Pharmaceuticals is trading at 5.04 as of the 15th of April 2024. This is a -1.18 percent decrease since the beginning of the trading day. The stock's open price was 5.1. Aurinia Pharmaceuticals has about a 29 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Aurinia Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of March 2024 and ending today, the 15th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 1999 | Category Healthcare | Classification Health Care |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has 144.62 M outstanding shares of which 12.24 M shares are presently shorted by private and institutional investors with about 7.53 trading days to cover. More on Aurinia Pharmaceuticals
Moving together with Aurinia Stock
| 0.68 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against Aurinia Stock
| 0.89 | RZLT | Rezolute Trending | PairCorr |
| 0.86 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.79 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
| 0.74 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.72 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
| 0.7 | BMY | Bristol Myers Squibb Financial Report 25th of April 2024 | PairCorr |
| 0.69 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Aurinia Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aurinia Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aurinia Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Stephen Zaruby | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Aurinia Pharmaceuticals report their recommendations after researching Aurinia Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Aurinia Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Aurinia Pharmaceuticals. The Aurinia consensus assessment is calculated by taking the average forecast from all of the analysts covering Aurinia Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Aurinia Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Aurinia Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Aurinia Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aurinia Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aurinia Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aurinia Pharmaceuticals' financial leverage. It provides some insight into what part of Aurinia Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aurinia Pharmaceuticals (AUPH) is traded on NASDAQ Exchange in USA. It is located in 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 and employs 300 people. Aurinia Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 737.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aurinia Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aurinia Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Aurinia Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 144.62 M outstanding shares of which 12.24 M shares are presently shorted by private and institutional investors with about 7.53 trading days to cover.
Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Aurinia Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAurinia Pharmaceuticals retains a total of 144.62 Million outstanding shares. 30% of Aurinia Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Aurinia Ownership Details
Aurinia Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Aurinia Pharmaceuticals jumping above the current price in 90 days from now is about 84.68%. The Aurinia Pharmaceuticals probability density function shows the probability of Aurinia Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Aurinia Pharmaceuticals has a beta of 0.4654. This suggests as returns on the market go up, Aurinia Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aurinia Pharmaceuticals will be expected to be much smaller as well. Additionally, aurinia Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Aurinia Pharmaceuticals to move above the current price in 90 days from now is about 84.68 (This Aurinia Pharmaceuticals probability density function shows the probability of Aurinia Stock to fall within a particular range of prices over 90 days) .
Aurinia Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Aurinia Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aurinia Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aurinia Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| International Biotechnology Trust Plc | 2023-09-30 | 1 M | |
| Schroder Investment Management Group | 2023-12-31 | 1 M | |
| Susquehanna International Group, Llp | 2023-12-31 | 1 M | |
| Balyasny Asset Management Llc | 2023-12-31 | 887 K | |
| Tang Capital Management Llc | 2023-09-30 | 750 K | |
| Group One Trading, Lp | 2023-12-31 | 678.8 K | |
| Woodline Partners Lp | 2023-12-31 | 645.2 K | |
| Citadel Advisors Llc | 2023-09-30 | 637.9 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 438.2 K | |
| Armistice Capital, Llc | 2023-12-31 | 9.5 M | |
| Blackrock Inc | 2023-12-31 | 8.9 M |
Aurinia Pharmaceuticals Historical Income Statement
Aurinia Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Aurinia's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Aurinia Pharmaceuticals revenue and expense. Aurinia Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Aurinia Pharmaceuticals' Total Revenue is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Gross Profit is estimated to increase to about 169.4 M, while Operating Income is forecasted to increase to (79.1 M). View More FundamentalsAurinia Stock Against Markets
Picking the right benchmark for Aurinia Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aurinia Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aurinia Pharmaceuticals is critical whether you are bullish or bearish towards Aurinia Pharmaceuticals at a given time. Please also check how Aurinia Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aurinia Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Aurinia Pharmaceuticals Corporate Directors
Aurinia Pharmaceuticals corporate directors refer to members of an Aurinia Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Aurinia Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Aurinia Pharmaceuticals' board members must vote for the resolution. The Aurinia Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Lorin Randall | Director | Profile | |
| George Milne | Director | Profile | |
| Benjamin Rovinski | Independent Director | Profile | |
| Michael Hayden | Director | Profile |
How to buy Aurinia Stock?
Before investing in Aurinia Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Aurinia Pharmaceuticals. To buy Aurinia Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Aurinia Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Aurinia Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Aurinia Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Aurinia Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Aurinia Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.
Already Invested in Aurinia Pharmaceuticals?
The danger of trading Aurinia Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aurinia Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aurinia Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aurinia Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Aurinia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.225 | Quarterly Revenue Growth 0.586 | Return On Assets (0.11) | Return On Equity (0.20) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.